(-0.05%) 5 476.00 points
(-0.09%) 38 784 points
(-0.01%) 19 920 points
(0.22%) $80.51
(1.33%) $2.83
(0.25%) $2 334.80
(-0.16%) $29.35
(-0.20%) $969.00
(-0.02%) $0.931
(-0.16%) $10.64
(0.05%) $0.788
(-1.86%) $86.81
Live Chart Being Loaded With Signals
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD)...
Stats | |
---|---|
Šios dienos apimtis | 1.79M |
Vidutinė apimtis | 1.22M |
Rinkos kapitalizacija | 9.56B |
EPS | $-0.700 ( Q1 | 2023-05-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-56.47 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $2.40 (1.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-16 | Hendrix Martin | Sell | 2 071 | Common Stock |
2023-06-16 | Hendrix Martin | Sell | 40 000 | Stock Option (right to buy) |
2023-06-16 | Hendrix Martin | Sell | 20 500 | Stock Option (right to buy) |
2023-06-16 | Laur James | Sell | 2 071 | Common Stock |
2023-06-16 | Laur James | Sell | 40 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
-86.91 |
Last 100 transactions |
Buy: 394 552 | Sell: 5 154 734 |
Tūris Koreliacija
Prometheus Biosciences, Koreliacija
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
PTE | -0.854 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Prometheus Biosciences, Koreliacija - Valiuta/Žaliavos
Prometheus Biosciences, Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $6.81M |
Bruto pelnas: | $6.81M (100.00 %) |
EPS: | $-3.49 |
FY | 2023 |
Pajamos: | $6.81M |
Bruto pelnas: | $6.81M (100.00 %) |
EPS: | $-3.49 |
FY | 2022 |
Pajamos: | $3.13M |
Bruto pelnas: | $3.13M (100.00 %) |
EPS: | $-2.87 |
FY | 2020 |
Pajamos: | $1.23M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.376 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Prometheus Biosciences,
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.